11.16Open11.16Pre Close0 Volume69 Open Interest135.00Strike Price0.00Turnover46.47%IV5.20%PremiumDec 20, 2024Expiry Date3.93Intrinsic Value100Multiplier4DDays to Expiry7.23Extrinsic Value100Contract SizeAmericanOptions Type0.7205Delta0.0462Gamma26.21Leverage Ratio-0.2858Theta0.0121Rho18.89Eff Leverage0.0527Vega
Glaukos Stock Discussion
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$
im seeing some decent chart upside here
thoughts?
$SciSparc (SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos (GKOS.US)$ gained 6% after We...
• $Canoo (GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $Aldeyra Therapeutics (ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $Westport Fuel (WPRT.US)$ +10.9% (awarded 38 mln program)
• $Greenwich LifeSciences (GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...
No comment yet